Results 31 to 40 of about 2,663 (168)

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients. [PDF]

Clin Pharmacol Ther
Escitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real‐life studies show a high degree of genotype–phenotype mismatch in escitalopram metabolism.
Hole K, Wollmann BM, Stingl JC, Molden E.   +3 more
europepmc   +2 more sources

Predicting Phenoconversion in Isolated RBD: Machine Learning and Explainable AI Approach

Clocks & Sleep
Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is recognized as a precursor to neurodegenerative diseases. This study aimed to develop predictive models for the timing and subtype of phenoconversion in iRBD.
Ki-Young Jung, Han-Joon Kim, Jun-Sang Sunwoo   +2 more
exaly   +3 more sources

Stereoselective Determination of Omeprazole and 5-Hydroxy-Omeprazole in Dried Blood Spots for CYP2C19 Activity Assessment. [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT We previously proposed stereoselective 5‐hydroxy‐omeprazole/omeprazole cut‐offs for R‐ and S‐omeprazole to differentiate between rapid, normal, and poor CYP2C19 metabolisers. However, the performance of these stereoselective CYP2C19 phenotyping approaches has never been compared with conventional racemic omeprazole phenotyping.
Hectors T, Abouir K, Varesio E, Manson ML, Daali Y, Samer C.   +5 more
europepmc   +2 more sources

Unawareness of motor phenoconversion in Huntington disease [PDF]

Neurology, 2013
To determine whether Huntington disease (HD) mutation carriers have motor symptoms (complaints) when definite motor onset (motor phenoconversion) is diagnosed and document differences between the groups with and without unawareness of motor signs.We analyzed data from 550 HD mutation carriers participating in the multicenter PREDICT-HD Study followed ...
Elizabeth A, McCusker, David G, Gunn, Eric A, Epping, Clement T, Loy, Kylie, Radford, Jane, Griffith, James A, Mills, Jeffrey D, Long, Jane S, Paulsen   +8 more
openaire   +2 more sources

Predictive risk factors of phenoconversion in idiopathic REM sleep behavior disorder: the Italian study "FARPRESTO" [PDF]

, 2022
Most patients with idiopathic REM sleep behavior disorder (iRBD) will develop an overt α-synucleinopathy over time, with a rate of phenoconversion of 73.5% after 12 years from diagnosis.
Figorilli M., Arnaldi D., Gigli G. L., d'Aloja E., Ferini-Strambi L., Maestri M., Antelmi Elena., and the FARPRESTO Consortium., Ferri R., Terzaghi M., Plazzi G., Antelmi E., Ingravallo F., Puligheddu M., Casaglia E., d’Aloja, Ernesto, Gigli, G. L., Casaglia, Elisa, Puligheddu, Monica, Arnaldi, Dario, Antelmi, Elena, d'Aloja, Ernesto, Ingravallo, Francesca, Plazzi, Giuseppe, Ferri, Raffaele, Gigli, Gian Luigi, Ferini-Strambi, Luigi, Figorilli, Michela, Terzaghi, Michele, Maestri, Michelangelo   +29 more
core   +3 more sources

Personality profile and its association with conversion to neurodegenerative disorders in idiopathic REM sleep behavior disorder

npj Parkinson's Disease, 2022
Patients with Parkinson’s disease (PD) were described less extraverted and more neurotic. It remained unclear whether similar personality traits could be found in idiopathic rapid eye movement sleep behavior disorder (iRBD), a prodromal stage of PD, and ...
Li Zhou, Steven W. H. Chau, Yaping Liu, Jing Wang, Jihui Zhang, Ngan Yin Chan, Joey W. Y. Chan, Bei Huang, Sijing Chen, Shirley Xin Li, Vincent Chung Tong Mok, Yun Kwok Wing   +11 more
doaj   +1 more source

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions

Pharmaceuticals, 2021
Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event.
Martina Hahn, Sibylle C. Roll
doaj   +1 more source

Predicting phenoconversion in pure autonomic failure

Neurology, 2020
To determine predicting factors and frequency of phenoconversion from pure autonomic failure (PAF) into a synucleinopathy with motor or cognitive involvement of multiple system atrophy (MSA), Parkinson disease (PD), or dementia with Lewy bodies (DLB).We performed a retrospective review of all patients with PAF from 2001 to 2011 evaluated at Mayo Clinic,
Elizabeth A, Coon, Jay N, Mandrekar, Sarah E, Berini, Eduardo E, Benarroch, Paola, Sandroni, Phillip A, Low, Wolfgang, Singer   +6 more
openaire   +3 more sources

Phenoconversion and therapeutic drug monitoring [PDF]

British Journal of Clinical Pharmacology, 2015
Keywords: clobazam; clozapine; genotype–phenotype mismatch; personalized medicine; pharmacogenetics; risperidone; therapeutic drug monitoring ...
openaire   +2 more sources

Pitfalls and challenges associated with phenoconversion in forensic toxcicology

Forensic Science International: Genetics, 2021
In recent years, several publications have demonstrated the interest and the usefulness of pharmacogenetics in forensic toxicology. However, this approach remains namely focused on DNA-based phenotype, which may potentially lead to misinterpretation.
Drevin, G., Picard, N., Jousset, N., Briet, M., Abbara, C.   +4 more
openaire   +3 more sources